Explore
13D/13G Activist Filings
118,738 resultsSome filings may show "N/A" for ticker if the subject is a private fund, SPAC, or unlisted security.
| Filed ↓ | Ticker | Company | Filer | Form | % Owned | Shares |
|---|---|---|---|---|---|---|
| Feb 17, 2026 | RLYB | Rallybio Corporation | VIKING GLOBAL INVESTORS LP | 13G/A | 10.0% | 4.2M |
| Feb 17, 2026 | CRCL | Circle Internet Group, Inc. | General Catalyst Group Management Holdings GP, LLC | 13G/A | 0.0% | 0 |
| Feb 17, 2026 | INBX | Inhibrx Biosciences, Inc. | VIKING GLOBAL INVESTORS LP | 13G/A | 10.0% | 1.5M |
| Feb 17, 2026 | WHLR | Wheeler Real Estate Investment Trust, Inc. | Magnetar Financial LLC | 13G/A | 9.8% | 206K |
| Feb 17, 2026 | PRMB | Primo Brands Corp | VIKING GLOBAL INVESTORS LP | 13G/A | 0.0% | 0 |
| Feb 17, 2026 | CCOI | COGENT COMMUNICATIONS HOLDINGS, INC. | Turtle Creek Asset Management Inc. | 13G/A | 8.2% | 4.0M |
| Feb 17, 2026 | SAIA | SAIA INC | VIKING GLOBAL INVESTORS LP | 13G/A | 4.1% | 1.1M |
| Feb 17, 2026 | BFH | BREAD FINANCIAL HOLDINGS, INC. | Turtle Creek Asset Management Inc. | 13G/A | 5.6% | 2.6M |
| Feb 17, 2026 | ATS | ATS Corp /ATS | Turtle Creek Asset Management Inc. | 13G/A | 5.8% | 5.6M |
| Feb 17, 2026 | ECPG | ENCORE CAPITAL GROUP, INC. | Turtle Creek Asset Management Inc. | 13G/A | 4.4% | 971K |
| Feb 17, 2026 | NAMS | NewAmsterdam Pharma Co N.V. | VIKING GLOBAL INVESTORS LP | 13G/A | 3.7% | 4.2M |
| Feb 17, 2026 | CLB | Core Laboratories Inc. /DE/ | DISCIPLINED GROWTH INVESTORS INC /MN | 13G/A | 11.1% | 5.2M |
| Feb 17, 2026 | WWW | Wolverine World Wide Inc /DE/ | Point72 Asset Management, L.P. | 13G/A | 1.5% | 1.2M |
| Feb 17, 2026 | GRAL | GRAIL, Inc. | Baker Bros. Advisors LP | 13G | 5.3% | 2.1M |
| Feb 17, 2026 | ADCT | ADC Therapeutics SA | TCG Crossover GP II, LLC | 13G | 9.2% | 11.4M |
| Feb 17, 2026 | DBRG | DigitalBridge Group, Inc. | Wafra Strategic Holdings LP | 13G/A | 1.4% | 2.7M |
| Feb 17, 2026 | NOV | NOV Inc. | Hotchkis and Wiley Capital Management, LLC | 13G/A | 8.9% | 32.5M |
| Feb 17, 2026 | FC | Franklin Covey Co | AllianceBernstein L.P. | 13G/A | 9.5% | 1.1M |
| Feb 17, 2026 | TENX | TENAX THERAPEUTICS, INC. | Point72 Asset Management, L.P. | 13G/A | 6.8% | 423K |
| Feb 17, 2026 | VTGN | Vistagen Therapeutics, Inc. | Commodore Capital LP | 13G/A | 9.9% | 4.4M |
| Feb 17, 2026 | FFIV | F5, INC. | Hotchkis and Wiley Capital Management, LLC | 13G/A | 9.4% | 5.5M |
| Feb 17, 2026 | IVVD | Invivyd, Inc. | Point72 Asset Management, L.P. | 13G/A | 6.0% | 16.7M |
| Feb 17, 2026 | ALKS | Alkermes plc. | Baker Bros. Advisors LP | 13G | 6.1% | 10.0M |
| Feb 17, 2026 | EYPT | Eyepoint, Inc. | TCG Crossover GP II, LLC | 13G/A | 4.3% | 3.6M |
| Feb 17, 2026 | APVO | Aptevo Therapeutics Inc. | Point72 Asset Management, L.P. | 13G/A | 0.0% | 0 |
| Feb 17, 2026 | EFX | Equifax Inc | HARRIS ASSOCIATES L P | 13G | 6.2% | 7.6M |
| Feb 17, 2026 | DNTH | Dianthus Therapeutics, Inc. | RA Capital Management, L.P. | 13G/A | 6.0% | 2.6M |
| Feb 17, 2026 | SEPN | Septerna, Inc. | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 2.0% | 920K |
| Feb 17, 2026 | GDOT | GREEN DOT CORP | No Street GP LP | 13G | 6.1% | 3.4M |
| Feb 17, 2026 | OLN | OLIN Corporation | Hotchkis and Wiley Capital Management, LLC | 13G/A | 13.4% | 15.3M |
| Feb 17, 2026 | PMN | ProMIS Neurosciences Inc. | Great Point Partners, LLC | 13G/A | 10.0% | 410K |
| Feb 17, 2026 | HESM | Hess Midstream LP | Harvest Fund Advisors LLC | 13G | 5.1% | 6.5M |
| Feb 17, 2026 | DLTR | DOLLAR TREE, INC. | EdgePoint Investment Group Inc. | 13G/A | 4.3% | 8.7M |
| Feb 17, 2026 | AVDL | AVADEL PHARMACEUTICALS PLC | Two Seas Capital LP | 13G/A | 0.0% | 0 |
| Feb 17, 2026 | SABS | SAB Biotherapeutics, Inc. | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 5.1% | 2.5M |
| Feb 17, 2026 | CTNM | Contineum Therapeutics, Inc. | RA Capital Management, L.P. | 13G/A | 7.2% | 2.2M |
| Feb 17, 2026 | N/A | M2i Global, Inc. | Executive Real Estate LLC | 13D | 45.3% | 600.0M |
| Feb 17, 2026 | CLMT | Calumet, Inc. | Two Seas Capital LP | 13G/A | 9.3% | 8.1M |
| Feb 17, 2026 | VCIC | Vine Hill Capital Investment Corp. | Highbridge Capital Management, LLC | 13G | 6.2% | 1.4M |
| Feb 17, 2026 | TNGX | Tango Therapeutics, Inc. | TCG Crossover GP II, L.P. | 13G/A | 10.0% | 13.5M |
| Feb 17, 2026 | DRUG | BRIGHT MINDS BIOSCIENCES INC. | Commodore Capital LP | 13G/A | 0.3% | 19K |
| Feb 17, 2026 | AMLX | Amylyx Pharmaceuticals Inc. | TCG Crossover GP II, LLC | 13G/A | 5.7% | 6.2M |
| Feb 17, 2026 | HVII | Hennessy Capital Investment Corp. VII | Highbridge Capital Management, LLC | 13G | 7.6% | 1.5M |
| Feb 17, 2026 | FGMC | FG Merger II Corp. | RIVERNORTH CAPITAL MANAGEMENT, LLC | 13G | 6.2% | 643K |
| Feb 17, 2026 | ALRM | Alarm.com Holdings, Inc. | DISCIPLINED GROWTH INVESTORS INC /MN | 13G/A | 6.9% | 3.4M |
| Feb 17, 2026 | MDRX | Veradigm Inc. | Two Seas Capital LP | 13G/A | 6.9% | 7.5M |
| Feb 17, 2026 | N/A | Monroe Federal Bancorp, Inc. | Monroe Federal Savings & Loan Association Employee Stock Ownership Plan Trust | 13G/A | 6.8% | 37K |
| Feb 17, 2026 | TWST | Twist Bioscience Corp | EdgePoint Investment Group Inc. | 13G/A | 8.8% | 5.4M |
| Feb 17, 2026 | FGMC | FG Merger II Corp. | Highbridge Capital Management, LLC | 13G | 5.4% | 560K |
| Feb 17, 2026 | PVLA | PALVELLA THERAPEUTICS, INC. | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 3.8% | 471K |